NDA 210496 · Array Biopharma INC
Braftovi
Encorafenib · Oral
NovelAccelerated approvalOrphanLast checked: Nov 20, 2026Latest source record: Feb 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jun 27, 2018
Approved uses
10
Original approval plus efficacy supplements
Registered trials
91
8 Phase 3, 20 recruiting
FAERS reports
10,191
7,170 serious, 1,700 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 26, 2026.
BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-authorized test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) • in combination with cetuximab and fluorouracil-based chemotherapy, for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑authorized test. ( 1.2 , 2.1 ) • in combination with cetuximab, for the treatment of adult patients with mCRC with a BRAF V600E mutation, as detected by an FDA-authorized test, after prior therapy. ( 1.2 , 2.1 ) Non-Small Cell Lung Cancer (NSCLC) • in combination with binimetinib, for the treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-authorized test. ( 1.3 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. ( 1.4 , 5.2 ) 1.1 BRAF V600E or V600K Mutation–Positive Unresectable or Metastatic Melanoma BRAFTOVI is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-authorized test [see Dosage and Administration (2.1) ] . 1.2 BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (mCRC) • BRAFTOVI is indicated, in combination with cetuximab and fluorouracil-based chemotherapy , for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA- authorized test [see Dosage and Administration (2.1) ]. • BRAFTOVI is indicated, in combination with cetuximab,...
Mechanism: Encorafenib is a kinase inhibitor that targets BRAF V600E, as well as wild-type BRAF and CRAF in in vitro cell-free assays with IC 50 values of 0.35, 0.47, and 0.3 nM, respectively. Mutations in the BRAF gene, such as BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth. Encorafenib was also able to bind to other kinases in vitro including JNK1, JNK2, JNK3, LIMK1, LIMK2, MEK4, and STK36 and reduce ligand binding to these kinases at clinically achievable concentrations (≤0.9 µM). Encorafenib inhibited in vitro growth of tumor cell lines...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 24, 2026 Supplement 19 · Efficacy LabelLetter
- Feb 24, 2026 Supplement 21 · Efficacy OrphanLabelMedication GuideLetter
- Mar 12, 2025 Supplement 18 · Efficacy OrphanLetterLabel
- Dec 20, 2024 Supplement 17 · Efficacy · priority review OrphanLabelLetterReview
- Sep 12, 2024 Supplement 16 · Efficacy OrphanLabelLetter
- Oct 11, 2023 Supplement 14 · Efficacy OrphanLabelLetter
- Apr 8, 2020 Supplement 6 · Efficacy · priority review LabelLetter
- May 24, 2019 Supplement 3 · Efficacy OrphanLabelLetter
- Jan 23, 2019 Supplement 1 · Efficacy OrphanLabelLetter
- Jun 27, 2018 Original approval · Type 1 - New Molecular Entity NovelAccelerated approvalOrphanLabelLetterReview
2 products under this application
- BRAFTOVI · ENCORAFENIB 50MG · CAPSULE, ORAL · Discontinued
- BRAFTOVI · ENCORAFENIB 75MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Encorafenib" as an intervention, any sponsor and status, largest first.
- Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant MelanomaPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01909453 · 921 participants · Start Sep 12, 2013 · Primary completion Nov 9, 2016
Drug: LGX818; MEK162 and 1 more · For: Melanoma
Sites: Birmingham, Alabama; Tucson, Arizona; Fayetteville, Arkansas · 282 sites in all
- A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT04607421 · 841 participants · Start Dec 21, 2020 · Primary completion Mar 1, 2025
Drug: Encorafenib; Cetuximab and 6 more · For: Neoplasms
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 274 sites in all
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.Pivotal-lookingActive, not recruiting
Pierre Fabre MedicamentIndustry
NCT05270044 · 815 participants (planned) · Start May 2, 2022 · Primary completion Mar 31, 2027
Drug: Encorafenib and Binimetinib; Placebo to match Encorafenib ; Placebo to match Binimetinib · For: Melanoma
Sites: CABA, Argentina; Mar del Plata, Argentina; Ciudad Autonoma Bs As, Argentina · 155 sites in all
- Personalized Medicine for Advanced Biliary Cancer PatientsPivotal-lookingRecruiting
UNICANCERAcademic, hospital or other
NCT05615818 · 800 participants (planned) · Start Jul 18, 2024 · Primary completion Jun 2027
Drug: Futibatinib; Ivosidenib and 8 more · For: Biliary Tract Neoplasms
Sites: Brussels, Belgium; Edegem, Belgium; Leuven, Belgium · 69 sites in all
PfizerPfizer (PFE)
NCT02928224 · 702 participants · Start Oct 13, 2016 · Primary completion Feb 11, 2019
Drug: Encorafenib; Binimetinib and 4 more · For: BRAF V600E-mutant Metastatic Colorectal Cancer
Sites: Phoenix, Arizona; Scottsdale, Arizona; Duarte, California · 418 sites in all
- Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerPivotal-lookingActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT03803553 · 400 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 2026
Drug: FOLFIRI Protocol; Nivolumab Protocol and 2 more · For: Metastatic Colon Cancer; Stage III Colon Cancer
Sites: Boston, Massachusetts; New York, New York · 3 sites in all
- Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and BinimetinibPivotal-lookingActive, not recruiting
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT03235245 · 271 participants · Start Oct 30, 2018 · Primary completion Oct 24, 2023
Drug: Nivolumab + Ipilimumab; Encorafenib + Binimetinib · For: Unresectable Stage III Melanoma; Stage IV Melanoma
Sites: Herlev, Denmark; Odense, Denmark; Helsinki, Finland · 38 sites in all
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT04657991 · 257 participants · Start Jan 15, 2021 · Primary completion Oct 30, 2026
Drug: Encorafenib; Binimetinib and 1 more · For: Melanoma
Sites: Orlando, Florida; Fairway, Kansas; Overland Park, Kansas · 151 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death1,201
- off label use1,142
- nausea872
- fatigue795
- diarrhoea652
- pyrexia615
- neoplasm progression553
- product use in unapproved indication523
- vomiting488
- rash486
- serous retinal detachment360
- arthralgia329
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 245 |
| 2019 | 1,312 |
| 2020 | 1,380 |
| 2021 | 1,146 |
| 2022 | 1,327 |
| 2023 | 1,390 |
| 2024 | 1,218 |
| 2025 | 1,239 |
| 2026 | 933 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Braftovi (Encorafenib)
2024 spending
$138M
Beneficiaries
1,872
9,510 claims
Per beneficiary
$73,773
$100.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $55,947,005 |
| 2021 | $85,249,323 |
| 2022 | $100,513,430 |
| 2023 | $87,193,016 |
| 2024 | $138,103,680 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.
Elez E, Yoshino T, Shen L, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Kopetz S, Grothey A, Yaeger R, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Comparative Study
- Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.
Kopetz S, Yoshino T, Van Cutsem E, et al. · Nat Med 2025 · Clinical Trial, Phase III, Multicenter Study
- Treatment of Metastatic Colorectal Cancer: ASCO Guideline.
Morris VK, Kennedy EB, Baxter NN, et al. · J Clin Oncol 2023 · Systematic Review
- Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
Tabernero J, Grothey A, Van Cutsem E, et al. · J Clin Oncol 2021 · Clinical Trial, Phase III, Multicenter Study
- COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Schadendorf D, Dummer R, Flaherty KT, et al. · Eur J Cancer 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Array Biopharma INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.